Lantern Pharma Inc.
LTRN
$2.51
$0.4521.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.13% | 15.00% | 10.05% | 6.78% | 1.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.08% | -7.20% | 4.91% | 10.01% | 24.27% |
| Operating Income | 19.08% | 7.20% | -4.91% | -10.01% | -24.27% |
| Income Before Tax | 17.62% | 0.90% | -8.46% | -13.36% | -30.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.62% | 0.90% | -8.46% | -13.36% | -30.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.62% | 0.90% | -8.46% | -13.36% | -30.19% |
| EBIT | 19.08% | 7.20% | -4.91% | -10.01% | -24.27% |
| EBITDA | 19.09% | 7.21% | -4.91% | -10.01% | -24.27% |
| EPS Basic | 18.38% | 1.59% | -8.02% | -13.26% | -30.62% |
| Normalized Basic EPS | 17.44% | 1.25% | -8.36% | -13.60% | -29.74% |
| EPS Diluted | 18.38% | 1.59% | -8.02% | -13.26% | -30.62% |
| Normalized Diluted EPS | 17.44% | 1.25% | -8.36% | -13.60% | -29.74% |
| Average Basic Shares Outstanding | -24.90% | 0.66% | 0.28% | -0.01% | -0.37% |
| Average Diluted Shares Outstanding | 0.21% | 0.66% | 0.28% | -0.01% | -0.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |